Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials

We examined insulin antibody formation in patients with type 1 (T1D) or type 2 diabetes (T2D) treated with once‐daily insulin degludec (IDeg) or insulin glargine (IGlar) to evaluate the impact of antibody formation on efficacy and safety. Insulin antibodies were measured using subtraction radioimmun...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Obes Metab
Autors principals: Vora, J., Seufert, J., Solberg, H., Kinduryte, O., Johansen, T., Hollander, P.
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2016
Matèries:
Research Letters
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5067686/
https://ncbi.nlm.nih.gov/pubmed/26663320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12621
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars